Indexed with PubMed and Science Citation Index (E) 
Users online: 367 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (95 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded443    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2006  |  Volume : 72  |  Issue : 2  |  Page : 173-174

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

Consultant Dermatologist, New Delhi, India

Correspondence Address:
J Sundharam
Office No. 1, 1st floor, K. D. Market, Pitampura, New Delhi 110 034
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.25656

Rights and Permissions

How to cite this article:
Sundharam J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol 2006;72:173-4

How to cite this URL:
Sundharam J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol [serial online] 2006 [cited 2020 Aug 8];72:173-4. Available from:

Since the 1960s, systemic corticosteroids with or without immunosuppressives have been the mainstay of therapy for the treatment of pemphigus. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects.

Rituximab belongs to the class of biologicals and is a specific mouse and human chimeric monoclonal antibody. This IgG1 has a long half-life of 76 to 200 h and targets the CD20 antigen. The CD 20 antigen is present on pre-B, immature and mature B cells and is important for B-cell activation and proliferation. Binding of rituximab to CD 20 results in complement- and antibody-dependent cytotoxicity and subsequent apoptosis of cells exhibiting this antigen. CD20 is not expressed on stem cells and plasma cells and hence depletion of the B-cell subpopulation is transient and does not affect immunoglobulin synthesis. Normal levels of total serum IgG are maintained and antibody levels against HSV 1/2 and VZV are not significantly affected after rituximab treatment.

Rituximab is approved for use in the treatment of relapsing and refractory follicular lymphoma, where it has been shown to be highly efficacious. There are reports of its use in the treatment of autoimmune antibody mediated disorders such as rheumatoid arthritis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, myasthenia gravis and Wegener's granulomatosis. One of the main advantages of rituximab is low toxicity. Mild allergic reactions, such as fever and chills, sometimes occur during the first infusion but frequently do not recur with subsequent infusions.

Rituximab was first used in paraneoplastic pemphigus by Borradori et al. in 2001.[1] In this case, the drug was used for the concurrent follicular B-cell lymphoma; with four infusions over one month, the paraneoplastic pemphigus improved dramatically. Since then, over 20 reports of its use in pemphigus vulgaris and pemphigus foliaceus have appeared, eight in the past year alone.[1],[2],[3],[4] All of these have been difficult-to-treat cases, many nonresponsive to conventional corticosteroids, pulse steroids, adjuvants (cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, etc.), plasmapheresis and intravenous immunoglobulin. Many of these patients were controllable only with high doses of steroids (over 60 mg/day prednisolone, often with adjuvants such as cyclosporine), but after the use of rituximab, the steroids could either be completely withdrawn or tapered to very low maintenance doses.

Rituximab is available in India as Mabthera® (Roche Products Ltd.) and is primarily used by oncologists. It is expensive and at this point of time, it is unlikely to replace the standard treatment in our country. However in patients nonresponsive to standard therapies, its use may be considered, especially in those who can afford the drug. It is given in a dose of 375 mg/m 2 as an intravenous infusion weekly for 4 weeks; in individual cases, further infusions may be necessary.

  References Top

1.Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269-72.   Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006;31:143.   Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: Current and emerging options. Am J Clin Dermatol 2005;6:327-42.   Back to cited text no. 3  [PUBMED]  
4.Arin MJ, Hunzelmann N. Anti-B-cell directed immunotherapy (rituximab) in the treatment of refractory pemphigus: An update. Eur J Dermatol 2005;15:224-30.   Back to cited text no. 4  [PUBMED]  [FULLTEXT]

This article has been cited by
1 Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007
Peterson, J.D., Chan, L.S.
Therapeutics and Clinical Risk Management. 2009; 5(1): 1-7
2 Biological agents targeting beyond TNF-alpha
Sharma, R., Sharma, C., Mahajan, A.
Indian Journal of Critical Care Medicine. 2008; 12(4): 181-189


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow